- $97.20m
- $88.92m
- $3.57m
Brief: Neuraxis - Files To Register Resale Of Up To 1,923,194 Shares Of Common Stock - SEC Filing
Brief: Neuraxis Inc Expects Net Sales Of About $1.6 Million For Three Months Ended March 31, 2026
Brief: Neuraxis Reports Strong Fourth Quarter And Full Year 2025 Financial Results
Brief: Neuraxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access To More Patients With Functional Abdominal Pain
Brief: Neuraxis Wins First FDA Nod for FD Pain Treatment
Brief: Neuraxis Terminates License Agreement With Masimo
Brief: Neuraxis Awarded First Ever FDA Clearance For The Treatment Of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
Brief: Rosalind Advisors, Inc. Reports 9.9% Stake In Neuraxis Inc As Of November 12- SEC Filing
Brief: NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label
Brief: NeurAxis Will Disclose In Form 10-K For Year Ended December 31, 2023, Material Weakness On Its Internal Controls Over Financial Reporting
Brief: NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device
Brief: Neuraxis Announces Pricing Of Initial Public Offering